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were classiﬁed by residential location (urban, suburban, rural).
Massachusetts has 351 cities and towns; 10% urban, 19%
rural, and 71% suburban. Hospital charges, adjusted by a
0.517 cost-to-charge ratio, medical inﬂation and geographic
factors are reported in 2007 US$. RESULTS: The cohort
(n = 53,604) had 92,776 asthma-related encounters (65% ED
visits) during the year. The proportion of ED visits for subur-
ban patients was signiﬁcantly (p < 0.05) lower. On average,
rural patients (2%) had 1.7 encounters (range: 1–11), 5.2
asthma-related care days and accrued $5280 per patient. Sub-
urban patients (46%) averaged 1.6 encounters (range: 1–29),
5.5 care days and $9325 per patient. Urban patients (52%) had
1.8 encounters (range: 1–50), 5.9 care days and $8736 per
patient, on average. Over the year, rural patients used 2768
inpatient days and 1582 ED hours accruing $4.9 million in
asthma-related care costs. Suburban patients accrued 66,823
hospital days, 45,954 ED hours and $116.6 million. Urban
patients used 74,359 hospital days and 46,196 ED hours in one
year, accruing $116.1 million. CONCLUSION: Most patients
were from urban locations; however those from suburban areas
had a higher ratio of inpatient stays to ED visits, which con-
tributed to the higher average asthma-related cost per suburban
patient.
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OBJECTIVES: The objective of this study was to compare costs
and effects of montelukast (MON) as add-on to inhaled corti-
costeroids (ICS) with long-acting â2 agonist (LABA) as add-on
to ICS in adult patients with asthma when compliance is taken
into consideration and from a Swedish health care sector per-
spective. METHODS: A health economic model was developed
to calculate the incremental cost utility ratio of MON com-
pared to the LABA salmeterol (SAL). Head-to-head data from
IMPACT, a two-year 48-week clinical study (N = 1490) of
patients with moderate asthma, was used in the model to esti-
mate the relative effectiveness of the two regimens. The relative
compliance for SAL was assumed to be 0.8 vs 1.0 for MON in
the base case scenario. The analysis included costs for drugs,
asthma events and adverse events. Event rates and asthma spe-
ciﬁc quality of life data for MON and SAL treated patients
were collected from the IMPACT trial, while resource utiliza-
tion and unit costs to treat the events were collected from local
sources. RESULTS: In comparison with SAL, MON is associ-
ated with somewhat higher cost, but has, due to similar efﬁcacy
and better compliance, better effectiveness (more prevented
attacks and more QALYs gain), less asthma-related hospitaliza-
tion, and less serious drug-related side effects. The incremental
cost per QALY for MON + ICS compared to SAL + ICS after
adjusting for relative compliance was 7 000 EUR per QALY in
the base case. CONCLUSION: When added to ICS, MON
compared to SAL shows a favorable cost-utility in Sweden.
This conclusion was stable for reasonable variations in the
modelling assumptions.
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OBJECTIVES: Asthma is a major public health problem with
considerable economic impact. The aim of this study was to asses
the extent of uncontrolled disease and associated medical costs in
severe asthma. METHODS: Data were obtained from the
PHARMO Record Linkage System (PHARMO RLS) which
includes drug dispensing and hospitalizations for 2 million sub-
jects in The Netherlands. Severe asthma patients (12–49 years)
were deﬁned as those who had used long-acting beta-agonists
and inhaled corticosteroids for over 200 days and short-acting
beta agonists for at least 100 days in 2004. Uncontrolled asthma
was deﬁned as a hospitalization for asthma or use of multiple,
short (<30 day) courses of oral corticosteroids. Reimbursed costs
of asthma drugs and hospitalizations were calculated. A matched
case-control analyses was performed to compare asthma treat-
ment of cases (hospitalized for asthma or multiple courses of oral
corticosteroids) and controls. RESULTS: A total of 4.7% of
patients receiving at least 2 asthma preparations in the previous
year had severe asthma. A total of 17.4% of these were deﬁned
as having uncontrolled asthma. Excess drug costs for uncon-
trolled asthma with hospitalization were €664 per patient per
year and €282 per patient per year for patients without hospi-
talization. Including hospital admission costs, excess costs were
over €10,000 per patient per year. Lack of control did not seem
to be caused by under-treatment. CONCLUSION: Poor control
of severe asthma leads to disproportionately increased direct
costs compared to controlled severe asthma, especially when
hospital admission is required. Hospitalized patients representing
2% of the patients with severe asthma are responsible for 23% of
the total direct costs.
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OBJECTIVES: It is estimated that over 4.6 million people suffer
from asthma in England and Wales at an estimated annual cost to
the National Health Service (NHS) of more than 889 million.
Beclometasone dipropionate (BDP) is the current mainstay of
inhaled corticosteroid (ICS) therapy for asthma, and approxi-
mately 80% of patients who are prescribed an ICS receive BDP.
However, chloroﬂuorocarbons (CFC), which are used as propel-
lants in the majority of BDP formulations, are now being phased
out in accordance with the Montreal Protocol, a global initiative
to reduce global warming. QVAR (BDP) utilises environmentally
safe hydroﬂuoroalkane (HFA) in its delivery system. It has
equivalent therapeutic effect at about half the daily dose of CFC
BDP due to superior lung penetration. The UK National Institute
for Health and Clinical Excellence (NICE) are currently apprais-
ing a broad number of ICS licensed for the treatment of chronic
asthma. At the time of the enactment of the Montreal Protocol,
when CFC-based BDP will no longer be manufactured, only HFA
based alternatives will be available. We wished to explore the
Abstracts A401
